Journal of Medical Imaging and Radiation Oncology最新文献

英文中文

Research productivity of RANZCR radiation oncology trainees from 2014 to 2023 2014 年至 2023 年 RANZCR 放射肿瘤学受训人员的研究生产率。

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-20 DOI: 10.1111/1754-9485.13752

Emma Jane Quinn, Daniel Roos, Melissa James, Sweet Ping Ng, Frank Saran, Sashendra Senthi, Yu Yang Soon, Wee Loon Ong

Introduction

The aim of this study was to describe the research productivity among RANZCR Radiation Oncology (RO) trainees.

Methods

Publicly available data on RO fellows, who were awarded the RANZCR fellowship between July 2014 and June 2023, was extracted from the RANZCR Annual Reports. Fellows who had qualified overseas and did not undertake full RANZCR training were excluded. A PubMed search was performed for publications by each fellow in the 5 years prior, and 6 months, after the estimated completion of training. Research productivity was defined as the number of first-author and any-author publications per trainee.

Results

In total, 168 eligible RO fellows were included in this study. 104 (62%) and 118 (70%) fellows had first-author and any-author publications during training, respectively. A total of 203 first-author and 308 unique any-author publications were identified, with mean first-author and any-author publications per trainee of 1.21 (SD = 2.37) and 2.02 (SD = 3.71), respectively. Trainee research was most commonly published in JMIRO (34% of first-author and 27% of any-author publications). There were significant differences in the number of first-author publications by gender (P = 0.04) and training jurisdictions (P = 0.03). There were also differences in the number of any-author publications by gender (P = 0.002) and training jurisdictions (P = 0.03). There was a significant increase in any-author publications over the 9-year study period (P = 0.005).

Conclusion

This is the first study evaluating research productivity among RO fellows during training. We identified disparities in research productivity by gender and training jurisdictions. This offers opportunities to tailor efforts to better support a vibrant and productive research culture across the RO training program.

导言：本研究旨在描述新西兰放射肿瘤研究所（RANZCR）受训人员的研究效率：从RANZCR年度报告中提取了2014年7月至2023年6月期间获得RANZCR研究员资格的RO研究员的公开数据。不包括在海外获得资格且未接受完整RANZCR培训的研究员。我们在 PubMed 上搜索了每位研究员在预计完成培训之前 5 年和之后 6 个月内发表的论文。研究效率被定义为每位受训人员发表的第一作者和任何作者的论文数量：本研究共纳入了 168 名符合条件的 RO 研究员。104名（62%）和118名（70%）学员在培训期间分别发表了第一作者和任何作者的论文。共有203篇第一作者论文和308篇任何作者论文被确认，每位学员发表的第一作者和任何作者论文的平均数量分别为1.21篇（标准差=2.37）和2.02篇（标准差=3.71）。受训人员的研究成果最常发表在《JMIRO》上（占第一作者论文的 34%，占任何作者论文的 27%）。第一作者发表论文的数量在性别（P = 0.04）和培训辖区（P = 0.03）方面存在明显差异。不同性别（P = 0.002）和培训辖区（P = 0.03）的任何作者发表的论文数量也存在差异。在 9 年的研究期间，任何作者发表的论文数量都有明显增加（P = 0.005）：这是第一项对区域研究员在培训期间的研究效率进行评估的研究。我们发现了不同性别和培训辖区的研究生产率差异。这为调整工作提供了机会，以更好地支持整个研究员培训计划中充满活力和富有成效的研究文化。

{"title":"Research productivity of RANZCR radiation oncology trainees from 2014 to 2023","authors":"Emma Jane Quinn, Daniel Roos, Melissa James, Sweet Ping Ng, Frank Saran, Sashendra Senthi, Yu Yang Soon, Wee Loon Ong","doi":"10.1111/1754-9485.13752","DOIUrl":"10.1111/1754-9485.13752","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The aim of this study was to describe the research productivity among RANZCR Radiation Oncology (RO) trainees.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Publicly available data on RO fellows, who were awarded the RANZCR fellowship between July 2014 and June 2023, was extracted from the RANZCR Annual Reports. Fellows who had qualified overseas and did not undertake full RANZCR training were excluded. A PubMed search was performed for publications by each fellow in the 5 years prior, and 6 months, after the estimated completion of training. Research productivity was defined as the number of first-author and any-author publications per trainee.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 168 eligible RO fellows were included in this study. 104 (62%) and 118 (70%) fellows had first-author and any-author publications during training, respectively. A total of 203 first-author and 308 unique any-author publications were identified, with mean first-author and any-author publications per trainee of 1.21 (SD = 2.37) and 2.02 (SD = 3.71), respectively. Trainee research was most commonly published in JMIRO (34% of first-author and 27% of any-author publications). There were significant differences in the number of first-author publications by gender (<i>P</i> = 0.04) and training jurisdictions (<i>P</i> = 0.03). There were also differences in the number of any-author publications by gender (<i>P</i> = 0.002) and training jurisdictions (<i>P</i> = 0.03). There was a significant increase in any-author publications over the 9-year study period (<i>P</i> = 0.005).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This is the first study evaluating research productivity among RO fellows during training. We identified disparities in research productivity by gender and training jurisdictions. This offers opportunities to tailor efforts to better support a vibrant and productive research culture across the RO training program.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 7","pages":"828-834"},"PeriodicalIF":2.2,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidental findings in research brain MRI: Definition, prevalence and ethical implications. 脑磁共振成像研究中的意外发现：定义、发生率和伦理意义。

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-20 DOI: 10.1111/1754-9485.13744

Kenneth J de Jong, Emma Poon, Michelle Foo, Julian Maingard, Hong Kuan Kok, Christen Barras, Anousha Yazdabadi, Benham Shaygi, Gregory J Fitt, Gary Egan, Mark Brooks, Hamed Asadi

Radiological incidental findings (IFs) are previously undetected abnormalities which are unrelated to the original indication for imaging and are unexpectedly discovered. In brain magnetic resonance imaging (MRI), the prevalence of IFs is increasing. By reviewing the literature on IFs in brain MRI performed for research purposes and discussing ethical considerations of IFs, this paper provides an overview of brain IF research results and factors contributing to inconsistencies and considers how the consent process can be improved from an ethical perspective. We found that despite extensive literature regarding IFs in research MRI of the brain, there are major inconsistencies in the reported prevalence, ranging from 1.3% to 99%. Many factors appear to contribute to this broad range: lack of standardised definition, participant demographics variance, heterogenous MRI scanner strength and sequences, reporter variation and results classification. We also found significant discrepancies in the review, consent and clinical communication processes pertaining to the ethical nature of these studies. These findings have implications for future studies, particularly those involving artificial intelligence. Further research, particularly in relation to MRI brain IFs would be useful to explore the generalisability of study results.

放射学意外发现（IFs）是指以前未发现的异常情况，这些异常情况与最初的成像适应症无关，而且是意外发现的。在脑磁共振成像（MRI）中，IFs 的发生率越来越高。通过回顾以研究为目的的脑磁共振成像中 IFs 的相关文献并讨论 IFs 的伦理因素，本文概述了脑 IF 的研究结果和导致不一致的因素，并从伦理角度探讨了如何改进同意程序。我们发现，尽管有大量文献涉及脑部核磁共振成像研究中的 IFs，但报告的发生率存在很大的不一致，从 1.3% 到 99% 不等。造成这一广泛范围的因素似乎有很多：缺乏标准化定义、参与者人口统计学差异、不同的 MRI 扫描仪强度和序列、报告者差异和结果分类。我们还发现，在与这些研究的伦理性质相关的审查、同意和临床沟通过程中存在重大差异。这些发现对未来的研究，尤其是涉及人工智能的研究具有启示意义。进一步的研究，尤其是与核磁共振成像脑中频有关的研究，将有助于探索研究结果的普遍性。

{"title":"Incidental findings in research brain MRI: Definition, prevalence and ethical implications.","authors":"Kenneth J de Jong, Emma Poon, Michelle Foo, Julian Maingard, Hong Kuan Kok, Christen Barras, Anousha Yazdabadi, Benham Shaygi, Gregory J Fitt, Gary Egan, Mark Brooks, Hamed Asadi","doi":"10.1111/1754-9485.13744","DOIUrl":"https://doi.org/10.1111/1754-9485.13744","url":null,"abstract":"<p><p>Radiological incidental findings (IFs) are previously undetected abnormalities which are unrelated to the original indication for imaging and are unexpectedly discovered. In brain magnetic resonance imaging (MRI), the prevalence of IFs is increasing. By reviewing the literature on IFs in brain MRI performed for research purposes and discussing ethical considerations of IFs, this paper provides an overview of brain IF research results and factors contributing to inconsistencies and considers how the consent process can be improved from an ethical perspective. We found that despite extensive literature regarding IFs in research MRI of the brain, there are major inconsistencies in the reported prevalence, ranging from 1.3% to 99%. Many factors appear to contribute to this broad range: lack of standardised definition, participant demographics variance, heterogenous MRI scanner strength and sequences, reporter variation and results classification. We also found significant discrepancies in the review, consent and clinical communication processes pertaining to the ethical nature of these studies. These findings have implications for future studies, particularly those involving artificial intelligence. Further research, particularly in relation to MRI brain IFs would be useful to explore the generalisability of study results.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Abstract 摘要

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-19 DOI: 10.1111/1754-9485.13766

引用次数: 0

The RANZCR Artificial Intelligence Committee: Position statement on autonomous AI RANZCR 人工智能委员会：关于自主人工智能的立场声明。

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-19 DOI: 10.1111/1754-9485.13756

Daniel Roos, Amy Yuen Meei Teh, Kirsten Fitzpatrick, Martin Gunn, the RANZCR Artificial Intelligence Committee

引用次数: 0

Abstract 摘要

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-18 DOI: 10.1111/1754-9485.13760

引用次数: 0

Abstract 摘要

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-18 DOI: 10.1111/1754-9485.13765

引用次数: 0

Abstract 摘要

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-18 DOI: 10.1111/1754-9485.13762

引用次数: 0

Abstract 摘要

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-18 DOI: 10.1111/1754-9485.13761

引用次数: 0

Ultrasound-stimulated microbubbles to enhance radiotherapy: A scoping review 超声刺激微气泡增强放疗效果：范围综述

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-09 DOI: 10.1111/1754-9485.13740

Giulia McCorkell, Terrence Piva, Declan Highgate, Masao Nakayama, Moshi Geso

Introduction

Primarily used as ultrasound contrast agents, microbubbles have recently emerged as a versatile therapeutic vector that can be ‘burst’ to deliver payloads in the presence of suitably optimised ultrasound fields. Ultrasound-stimulated microbubbles (USMB) have recently demonstrated improvements in treatment outcomes across a variety of clinical applications. This scoping review investigates whether this potential translates into the context of radiation therapy by evaluating the application of this technology across all three phases of radiation action.

Methods

Primary research articles, excluding poster presentations and conference proceedings, were identified through systematic searches of the PubMed NCBI/Medline, Embase/OVID, Web of Science and CINAHL/EBSCOhost databases, with additional articles identified via manual Google Scholar searching. Articles were dual screened for inclusion using the Covidence systematic review platform and classified against all three phases of radiation action.

Results

Overall, 57 eligible publications from a total of 1389 identified articles were included in the review, with studies dating back to 2012. Study heterogeneity prevented formal statistical analysis; however, most articles reported improved outcomes using USMB in the presence of radiation compared to that of radiation alone. These improvements appear to result from the use of USMB as either a biovascular disruptor causing tumour cell damage via indirect mechanisms, or as a localised treatment vector that directly increases tumour cell uptake of other therapeutic and physical agents designed to enhance radiation action.

Conclusions

USMB demonstrate exciting potential to enhance the effects of radiation treatments due to their versatility and capacity to target all three phases of radiation action.

导言：微气泡主要用作超声造影剂，最近已成为一种多功能治疗载体，可在适当优化的超声场中 "迸发 "释放有效载荷。最近，超声刺激微泡（USMB）在各种临床应用中的治疗效果都有所改善。方法通过系统搜索 PubMed NCBI/Medline、Embase/OVID、Web of Science 和 CINAHL/EBSCOhost 数据库来确定主要研究文章（不包括海报展示和会议论文集），并通过手动搜索 Google Scholar 来确定其他文章。文章通过Covidence系统性综述平台进行双重筛选，并根据辐射行动的所有三个阶段进行分类。结果综述共收录了1389篇符合条件的文章中的57篇，研究时间可追溯到2012年。由于研究存在异质性，因此无法进行正式的统计分析；不过，大多数文章报告称，与单纯放射治疗相比，在放射治疗的同时使用 USMB 可改善疗效。这些改善似乎是由于 USMB 作为一种生物血管破坏剂，通过间接机制造成肿瘤细胞损伤，或者作为一种局部治疗载体，直接增加肿瘤细胞对旨在增强辐射作用的其他治疗和物理制剂的吸收。

{"title":"Ultrasound-stimulated microbubbles to enhance radiotherapy: A scoping review","authors":"Giulia McCorkell, Terrence Piva, Declan Highgate, Masao Nakayama, Moshi Geso","doi":"10.1111/1754-9485.13740","DOIUrl":"10.1111/1754-9485.13740","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Primarily used as ultrasound contrast agents, microbubbles have recently emerged as a versatile therapeutic vector that can be ‘burst’ to deliver payloads in the presence of suitably optimised ultrasound fields. Ultrasound-stimulated microbubbles (USMB) have recently demonstrated improvements in treatment outcomes across a variety of clinical applications. This scoping review investigates whether this potential translates into the context of radiation therapy by evaluating the application of this technology across all three phases of radiation action.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Primary research articles, excluding poster presentations and conference proceedings, were identified through systematic searches of the PubMed NCBI/Medline, Embase/OVID, Web of Science and CINAHL/EBSCOhost databases, with additional articles identified via manual Google Scholar searching. Articles were dual screened for inclusion using the Covidence systematic review platform and classified against all three phases of radiation action.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 57 eligible publications from a total of 1389 identified articles were included in the review, with studies dating back to 2012. Study heterogeneity prevented formal statistical analysis; however, most articles reported improved outcomes using USMB in the presence of radiation compared to that of radiation alone. These improvements appear to result from the use of USMB as either a biovascular disruptor causing tumour cell damage via indirect mechanisms, or as a localised treatment vector that directly increases tumour cell uptake of other therapeutic and physical agents designed to enhance radiation action.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>USMB demonstrate exciting potential to enhance the effects of radiation treatments due to their versatility and capacity to target all three phases of radiation action.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 6","pages":"740-769"},"PeriodicalIF":2.2,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.13740","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142203973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term outcomes and risk profile of cT3N0 breast cancer treated with neoadjuvant chemotherapy and curative surgery 采用新辅助化疗和根治性手术治疗 cT3N0 乳腺癌的长期疗效和风险概况

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Imaging and Radiation Oncology

Pub Date : 2024-09-09 DOI: 10.1111/1754-9485.13746

Young Seob Shin, Jae Ho Jeong, Il Yong Chung, Jaeha Lee, Su Ssan Kim, Seung Do Ahn, Jong Won Lee, Byung Ho Son, Jinhong Jung

Introduction

We evaluated the treatment outcomes and failure patterns in cT3N0 breast cancer patients classified for rigorous pretreatment evaluation and treated with neoadjuvant chemotherapy (NAC) and curative surgery.

Methods

We reviewed the records of 87 cT3N0 breast cancer patients who received NAC and curative surgery between 2000 and 2015. The clinical high-risk group was defined as having two or more risk factors: age < 40, histologic grade 3, lymphovascular invasion, hormone receptor negativity, and Ki-67 labeling index >20%.

Results

Of the patients, 84 (96.6%) and 79 (90.8%) were initially evaluated using magnetic resonance imaging and positron emission tomography/computed tomography. Most patients received anthracycline based NAC regimen (n = 69, 79.3%) and modified radical mastectomy (n = 61, 70.1%). During a 91.5-month median follow-up, ten patients experienced distant metastasis (DM) only, two had isolated local recurrence, one had local recurrence and DM, and another had local recurrence, regional recurrence, and DM. The 5-year rates of locoregional recurrence, DM, any recurrence (AR), and overall survival (OS) were 1.2%, 11.6%, 11.6%, and 90.8%, respectively. The risk group was an independent prognostic factor of recurrence, and the high-risk group had worse rates of DM (19.2% vs. 0%, P = 0.009), AR (19.2% vs. 0%, P = 0.016) and OS (82.8% vs. 100%, P = 0.001).

Conclusion

Patients with cT3N0 breast cancer classified for rigorous pretreatment evaluation and treated with NAC and radical surgery had favourable oncological outcomes. A clinical risk group based on clinical and immunohistochemical risk factors was an excellent predictor of survival and recurrence.

方法我们回顾了2000年至2015年间接受新辅助化疗（NAC）和根治性手术治疗的87例cT3N0乳腺癌患者的病历。临床高危组被定义为具有两个或两个以上风险因素：年龄< 40岁、组织学分级3级、淋巴管侵犯、激素受体阴性和Ki-67标记指数>20%。结果在患者中，84人（96.6%）和79人（90.8%）通过磁共振成像和正电子发射断层扫描/计算机断层扫描进行了初步评估。大多数患者接受了以蒽环类药物为基础的 NAC 方案（69 例，79.3%）和改良根治性乳房切除术（61 例，70.1%）。在91.5个月的中位随访期间，10名患者仅出现远处转移（DM），2名患者出现孤立的局部复发，1名患者出现局部复发和DM，另一名患者出现局部复发、区域复发和DM。5年的局部复发率、DM率、任何复发率（AR）和总生存率（OS）分别为1.2%、11.6%、11.6%和90.8%。风险组是复发的独立预后因素，高风险组的DM（19.2%对0%，P=0.009）、AR（19.2%对0%，P=0.016）和OS（82.8%对100%，P=0.001）率较低。根据临床和免疫组化风险因素划分的临床风险组是生存和复发的绝佳预测指标。

{"title":"Long-term outcomes and risk profile of cT3N0 breast cancer treated with neoadjuvant chemotherapy and curative surgery","authors":"Young Seob Shin, Jae Ho Jeong, Il Yong Chung, Jaeha Lee, Su Ssan Kim, Seung Do Ahn, Jong Won Lee, Byung Ho Son, Jinhong Jung","doi":"10.1111/1754-9485.13746","DOIUrl":"10.1111/1754-9485.13746","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>We evaluated the treatment outcomes and failure patterns in cT3N0 breast cancer patients classified for rigorous pretreatment evaluation and treated with neoadjuvant chemotherapy (NAC) and curative surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed the records of 87 cT3N0 breast cancer patients who received NAC and curative surgery between 2000 and 2015. The clinical high-risk group was defined as having two or more risk factors: age < 40, histologic grade 3, lymphovascular invasion, hormone receptor negativity, and Ki-67 labeling index >20%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the patients, 84 (96.6%) and 79 (90.8%) were initially evaluated using magnetic resonance imaging and positron emission tomography/computed tomography. Most patients received anthracycline based NAC regimen (<i>n</i> = 69, 79.3%) and modified radical mastectomy (<i>n</i> = 61, 70.1%). During a 91.5-month median follow-up, ten patients experienced distant metastasis (DM) only, two had isolated local recurrence, one had local recurrence and DM, and another had local recurrence, regional recurrence, and DM. The 5-year rates of locoregional recurrence, DM, any recurrence (AR), and overall survival (OS) were 1.2%, 11.6%, 11.6%, and 90.8%, respectively. The risk group was an independent prognostic factor of recurrence, and the high-risk group had worse rates of DM (19.2% vs. 0%, <i>P</i> = 0.009), AR (19.2% vs. 0%, <i>P</i> = 0.016) and OS (82.8% vs. 100%, <i>P</i> = 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with cT3N0 breast cancer classified for rigorous pretreatment evaluation and treated with NAC and radical surgery had favourable oncological outcomes. A clinical risk group based on clinical and immunohistochemical risk factors was an excellent predictor of survival and recurrence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 7","pages":"819-827"},"PeriodicalIF":2.2,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142203975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Medical Imaging and Radiation Oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀